Shopping Cart
- Remove All
Your shopping cart is currently empty
JZP-361
🥰Excellent
Catalog No. T27703Cas No. 1680193-80-9
Alias JZP361, JZP 361
JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.
JZP-361
🥰Excellent
Purity: 99.41%
Catalog No. T27703Alias JZP361, JZP 361Cas No. 1680193-80-9
JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $38 | In Stock | |
| 10 mg | $59 | In Stock | |
| 25 mg | $118 | In Stock | |
| 50 mg | $197 | In Stock | |
| 100 mg | $296 | In Stock | |
| 200 mg | $419 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "JZP-361"
KML29
T40521380424-42-9
KML29 is highly selective and effective monoacylglycerol lipase (MAGL) inhibitor. It has effective inhibition of human/mouse/rat MAGL (IC50: 5.9/15/43 nM). It has not inhibitory for FAAH (IC50 > 50 μM). It also effectively and selectively blocks hydrolysis of 2-arachidonoylglycerol (2-AG) in mice (IC50: 2.5 nM, 2-AG; >50 μM, AEA).
- $40
Size
QTY
XEN445
XEN-445, XEN 445
T22491515856-92-4
XEN445, a potent and selective endothelial lipase(EL) inhibitor (IC50=0.237 uM), exhibitis good ADME and PK properties.
- $33
Size
QTY
URB602
T3591565460-15-3
URB602 is a specific monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL (IC50: 28±4 μM) through a noncompetitive mechanism.
- $38
Size
QTY
ABX-1431
Elcubragistat
T53531446817-84-0
ABX-1431 (Elcubragistat) is a selective and orally available CNS-penetrant monoacylglycerol lipase (MAGL/MGLL) inhibitor (IC50: 14 nM).
- $30
Size
QTY
Atglistatin
Cited
T18751469924-27-3
Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.
- $34
Size
QTY
CitedAA38-3
1-Piperidinecarboxylic acid, 4-nitrophenyl ester
T937465815-76-1
AA38-3 (1-Piperidinecarboxylic acid, 4-nitrophenyl ester) inhibites three SHs (ABHD6, ABHD11, and FAAH)
- $38
Size
QTY
JJKK 048
T156141515855-97-6In house
JJKK 048 is a potent and selective MAGL inhibitor.
- $30
Size
QTY
MAGL-IN-4
His121 ARG57
T96872135785-20-3
MAGL-IN-4 (His121 ARG57) is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.
- $143
Size
QTY
Beta-Sitosterol
β-Sitosterol, SKF 14463, Cupreol, Beta-Sitosterol, Betaprost, Azuprostat, 22,23-Dihydrostigmasterol
T296683-46-5
Beta-Sitosterol (SKF 14463) has recently been shown to induce G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways. Beta-Sitosterol (SKF 14463) , a main dietary phytosterol found in plants, may have the potential for prevention and therapy for human cancer. Although the exact mechanism of action of Beta-Sitosterol (SKF 14463) is unknown, it may be related to cholesterol metabolism or anti-inflammatory effects (via interference with prostaglandin metabolism). Beta-Sitosterol (SKF 14463) induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells.
- $60
Size
QTY
Endothelial lipase inhibitor-1
T111991466427-02-0In house
Endothelial lipase inhibitor-1 is a potent inhibitor of endothelial lipase with an IC50 of 49 nM.
- $115
Size
QTY
NG-497
NG497
T734992598242-66-9
NG-497 is a selective, small molecule inhibitor of human adipose triglyceride lipase (ATGL) that targets the enzymatically active patatin-like structural domain of human ATGL.NG-497 binds ATGL in a hydrophobic lumen adjacent to the active site.NG-497 abrogates lipolysis in human adipocytes in a dose-dependent and reversible manner.NG-497 has been shown to be useful in cancer research. can be used in cancer research.
- $59
Size
QTY
Select Batch
Purity:99.41%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma. |
| Targets&IC50 | H1 receptor:6.81 (pA2), MAGL (human):46 nM, ABHD6 (human):1.79 μM, FAAH (human):7.24 μM |
| In vitro | JZP-361 shows the affinity of H1 antagonistic with a pA2 of 6.81). JZP-361(≤10 μM) does not show cannabinoid receptor activity. JZP-361 displays favorable interactions within the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole[1]. |
| Alias | JZP361, JZP 361 |
| Molecular Weight | 405.88 |
| Formula | C22H20ClN5O |
| Cas No. | 1680193-80-9 |
| Smiles | Clc1ccc2c(CCc3cccnc3C2=C2CCN(CC2)C(=O)n2cncn2)c1 |
| Relative Density. | 1.41 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 36.5 mg/mL (89.93 mM), Sonication is recommended. DMSO: 1 mg/mL (2.46 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
| ||||||||||||||||||||||||||||||||||||
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy JZP-361 | purchase JZP-361 | JZP-361 cost | order JZP-361 | JZP-361 chemical structure | JZP-361 in vitro | JZP-361 formula | JZP-361 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.